Last updated on April 2019

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies


Brief description of study

This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced B-cell malignancies. This study is divided into 2 parts: Part 1 (dose-confirmation phase) and Part 2 (dose-expansion phase).

Clinical Study Identifier: NCT03198650

Find a site near you

Start Over

Research Site

Chiba-shi, Japan
  Connect »

Research Site

Fukuoka-shi, Japan
  Connect »

Research Site

Isehara-shi, Japan
  Connect »

Research Site

Izumo-shi, Japan
  Connect »

Research Site

Nagoya-shi, Japan
  Connect »

Research Site

Niigata-shi, Japan
  Connect »

Research Site

Okayama-shi, Japan
  Connect »

Research Site

Sapporo-shi, Japan
  Connect »

Research Site

Sendai-shi, Japan
  Connect »

Research Site

Shimotsuke-shi, Japan
  Connect »

Research Site

Suita-shi, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.